Halozyme Therapeutics, Inc.
HALOHalozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative biologic and drug delivery technologies. They are known for their enzyme-based platforms that enhance the absorption and distribution of therapeutic proteins and peptides, supporting the development of targeted cancer treatments, autoimmune disorders, and other medical conditions. The company's proprietary enzyme, ENHANZE, is used in collaborations with major pharmaceutical companies to improve the efficacy and administration of various biologics.
Company News
Renaissance Group initiated a new $35.11 million position in Halozyme Therapeutics, acquiring 478,735 shares representing 1.32% of its U.S. equity assets. The biotech company offers innovative drug delivery technology and has demonstrated strong financial performance with consistent sales growth.
Acumen Pharmaceuticals will report its Q3 2025 financial results on November 12, 2025, hosting a conference call and webcast to provide a business and financial update. The company is developing a novel therapeutic targeting toxic amyloid beta oligomers for Alzheimer's disease treatment.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. JP Morgan analyst Matthew Boss downgraded the rating for Vail Resorts, Inc. (NYSE:MTN) from Neutral to Underweight, while cutting the price targ...
